Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-10-17Clinical Trial Update: A Feasibility Study of Group Metacognitive Therapy Versus Mindfulness Meditation Therapy [NA]
A completed feasibility trial comparing group metacognitive therapy to mindfulness meditation therapy for generalized anxiety disorder.
-
CLINICAL_TRIALS trial_result · 2016-10-06Clinical Trial Update: Brief Behavioral Treatment for Anxiety in Young Children [Phase 1, Phase 2]
This clinical trial update reports the completion of Phase 1 and Phase 2 evaluations of Brief Behavioral Treatment for Anxiety in young chil…
-
CLINICAL_TRIALS research · 2016-09-27Clinical Trial Update: Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis
A clinical trial update presenting an individual patient data meta-analysis assessing baseline severity and antidepressant efficacy across s…
-
CLINICAL_TRIALS trial_result · 2016-08-25Clinical Trial Update: Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults [NA]
A completed clinical trial evaluated antidepressant treatment in combination with cognitive behavioral therapy for generalized anxiety disor…
-
CLINICAL_TRIALS trial_result · 2016-08-19Clinical Trial Update: Repetitive Magnetic Transcranial Stimulation (rTMS) in the Treatment of Generalized Anxiety Disorder (GAD) [Phase 3]
A Phase 3 trial evaluating repetitive magnetic transcranial stimulation for generalized anxiety disorder has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-08-08Clinical Trial Update: A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder [Phase 4]
A Phase 4 pilot study evaluated cranial electrotherapy stimulation for generalized anxiety disorder; the study status is completed.
-
FDA approval · 2016-08-03FDA Approved: DULOXETINE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' original application for a generic duloxetine product. Duloxetine is used to treat multiple conditi…
-
CLINICAL_TRIALS trial_result · 2016-07-11Clinical Trial Update: Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety [Phase 4]
A Phase 4 trial comparing sertraline with cognitive behavioral therapy for generalized anxiety disorder was terminated.
-
FDA approval · 2016-06-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Vertical Pharmaceuticals, LLC)
FDA approved a supplemental application for venlafaxine hydrochloride (Vertical Pharmaceuticals, LLC). This action expands the sponsor's NDA…
-
CLINICAL_TRIALS research · 2016-06-15Clinical Trial Update: Effects of Saffron on Mild to Moderate Generalized Anxiety Disorder (GAD) [Phase 2, Phase 3]
A phase 2/3 clinical trial is evaluating saffron extract for patients with mild to moderate generalized anxiety disorder; the current status…
-
FDA approval · 2016-06-10FDA Approved: PAROXETINE — Original Application (Chartwell RX, LLC)
The FDA approved Chartwell RX, LLC's original ANDA for paroxetine (paroxetine hydrochloride), establishing a generic version of the antidepr…
-
CLINICAL_TRIALS trial_result · 2016-05-25Clinical Trial Update: An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder [Phase 2]
Phase 2 trial assessing the efficacy and tolerability of two doses of SSR149415 in outpatients with generalized anxiety disorder; the study …
-
CLINICAL_TRIALS trial_result · 2016-05-24Clinical Trial Update: An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder [Phase 3]
Phase 3 clinical trial update reporting completion of an eight-week study evaluating two doses of saredutant in adults with generalized anxi…
-
CLINICAL_TRIALS trial_result · 2016-05-24Clinical Trial Update: An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder [Phase 3]
Phase 3 trial evaluating efficacy and safety of saredutant in generalized anxiety disorder has completed.
-
CLINICAL_TRIALS research · 2016-05-06Clinical Trial Update: Internet-delivered Transdiagnostic Intervention for Anxiety and Depression [NA]
This clinical trial update describes an internet-delivered transdiagnostic intervention for anxiety and depression, covering multiple disord…
-
CLINICAL_TRIALS trial_result · 2016-05-02Clinical Trial Update: An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay [NA]
Open-label study evaluating the clinical utility and patient outcomes of the Genecept Assay in treatment-resistant depression and generalize…
-
FDA approval · 2016-04-07FDA Approved: XANAX XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for XANAX XR (alprazolam) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2016-04-06Clinical Trial Update: Venlafaxine PK Following Bariatric Surgery [Phase 4]
Phase 4 study evaluating how bariatric surgery affects the pharmacokinetics of venlafaxine has completed, assessing changes in drug exposure…
-
CLINICAL_TRIALS trial_result · 2016-04-05Clinical Trial Update: Correlation Between Sagittal Balance of the Spine and Psychopathological Profile
A terminated clinical trial from University Hospital Strasbourg investigated whether sagittal spine alignment correlates with psychopatholog…
-
FDA approval · 2016-03-31FDA Approved: ESCITALOPRAM — Original Application (Macleods Pharmaceuticals Limited)
FDA approved the original application for escitalopram from Macleods Pharmaceuticals Limited (generic escitalopram).
-
FDA approval · 2016-03-23FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for escitalopram oxalate from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2016-02-29FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) submitted by Viatris Specialty LLC.
-
FDA approval · 2016-02-29FDA Approved: BUSPIRONE HCL — Supplemental Application (Advagen Pharma Ltd)
FDA approved Advagen Pharma Ltd's supplemental application for Buspirone HCl (buspirone hydrochloride).
-
CLINICAL_TRIALS trial_result · 2016-02-23Clinical Trial Update: Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder [NA]
A completed clinical trial at Concordia University investigating beliefs about uncertainty in the treatment of Generalized Anxiety Disorder;…
-
FDA approval · 2016-02-02FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Camber Pharmaceuticals to offer escitalopram oxalate as a generic antidepressant, expanding …